University of Texas Health Science Center
Division of University of Texas
Latest From University of Texas Health Science Center
Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in a Phase III study of adult patients with a rare, bacteria-driven lung disease.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.